MCID: SMT003
MIFTS: 52

Somatostatinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Somatostatinoma

MalaCards integrated aliases for Somatostatinoma:

Name: Somatostatinoma 38 12 76 53 59 55 44 15 73
Somatostatin-Secreting Pancreatic Neoplasm 53
Somatomedin-Secreting Carcinoid 53
Pancreatic Endocrine Carcinoma 73
Pancreatic Somatostatinoma 73
Somatostatin Cell Neoplasm 12
Malignant Islet Cell Tumor 53
Ampullary Somatostatinoma 53
Carcinoid Somatostatinoma 53
Somatostatin Cell Tumour 12

Characteristics:

Orphanet epidemiological data:

59
somatostatinoma
Prevalence: <1/1000000 (Europe); Age of onset: Adult;

Classifications:



Summaries for Somatostatinoma

MalaCards based summary : Somatostatinoma, also known as somatostatin-secreting pancreatic neoplasm, is related to pancreatic somatostatinoma and duodenal somatostatinoma, and has symptoms including diarrhea An important gene associated with Somatostatinoma is SST (Somatostatin), and among its related pathways/superpathways is Neuroscience. The drugs Levoleucovorin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and liver, and related phenotypes are diabetes mellitus and nausea and vomiting

Wikipedia : 76 Somatostatinoma is a malignant tumor of the delta cells of the endocrine pancreas that produces... more...

Related Diseases for Somatostatinoma

Diseases related to Somatostatinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)
# Related Disease Score Top Affiliating Genes
1 pancreatic somatostatinoma 33.2 CALCA ENO2 SST
2 duodenal somatostatinoma 32.9 CALCA ENO2 INS SST
3 paraganglioma 30.2 CHGA ENO2 SST
4 horseshoe kidney 29.8 CHGA ENO2
5 multiple endocrine neoplasia 29.7 CALCA CHGA
6 carcinoid tumors, intestinal 29.7 CHGA ENO2 SST
7 merkel cell carcinoma 29.7 CHGA ENO2 SST
8 glucagonoma 29.6 CHGA SST VIP
9 carcinoid syndrome 29.5 CALCA CHGA ENO2 SST
10 gastrinoma 29.4 CHGA INS SST VIP
11 thyroid carcinoma, familial medullary 29.2 CALCA CHGA ENO2 SST
12 neuroendocrine tumor 29.2 CALCA CHGA ENO2 SST
13 islet cell tumor 29.2 CALCA CHGA INS SST VIP
14 pheochromocytoma 28.7 CALCA CHGA ENO2 EPAS1 SST VIP
15 jejunal somatostatinoma 12.1
16 multiple paragangliomas associated with polycythemia 11.4
17 pancreatic neuroendocrine tumor 11.1
18 neurofibromatosis, type i 10.3
19 polycythemia 10.2
20 postural hypotension 10.2 INS SST
21 pancreatic endocrine carcinoma 10.2 INS SST
22 hyperpituitarism 10.2 INS SST
23 dumping syndrome 10.2 INS SST
24 mongolian spot 10.1 ENO2 SST
25 adenoma of the pancreas 10.1 CHGA SST
26 functional gastric disease 10.1 INS SST
27 gastrointestinal neuroendocrine benign tumor 10.1 CHGA SST
28 retroperitoneal neuroblastoma 10.1 ENO2 SST
29 gastrointestinal neuroendocrine tumor 10.1 CHGA SST
30 gastric neuroendocrine neoplasm 10.1 CHGA SST
31 vein disease 10.1 EPAS1 SST
32 pituitary carcinoma 10.1 CHGA SST
33 endocrine pancreas disease 10.1 INS SST
34 pancreatoblastoma 10.1 CHGA SST
35 pancreas disease 10.1 INS SST
36 pituitary-dependent cushing's disease 10.1 INS SST
37 zollinger-ellison syndrome 10.1 CHGA SST
38 duodenum cancer 10.1 ENO2 SST
39 pituitary gland disease 10.1 INS SST
40 ileum cancer 10.1 ENO2 SST
41 hyperinsulinemic hypoglycemia 10.1 INS SST
42 serotonin syndrome 10.1 CHGA SST
43 retinal hemangioblastoma 10.1 ENO2 EPAS1
44 urinary bladder small cell neuroendocrine carcinoma 10.1 CHGA ENO2
45 intracranial primitive neuroectodermal tumor 10.1 CHGA ENO2
46 auditory system cancer 10.1 CHGA ENO2
47 gallbladder small cell carcinoma 10.1 CHGA ENO2
48 duodenal ulcer 10.1 INS SST
49 small cell carcinoma of the bladder 10.1 CHGA ENO2
50 epithelioid malignant peripheral nerve sheath tumor 10.1 CHGA ENO2

Comorbidity relations with Somatostatinoma via Phenotypic Disease Network (PDN):


Pancreatic Cancer

Graphical network of the top 20 diseases related to Somatostatinoma:



Diseases related to Somatostatinoma

Symptoms & Phenotypes for Somatostatinoma

Human phenotypes related to Somatostatinoma:

59 32 (show all 36)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0000819
2 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
3 constipation 59 32 frequent (33%) Frequent (79-30%) HP:0002019
4 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
5 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
6 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
7 increased circulating gonadotropin level 59 32 very rare (1%) Very rare (<4-1%) HP:0000837
8 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
9 intestinal obstruction 59 32 occasional (7.5%) Occasional (29-5%) HP:0005214
10 chronic fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012432
11 gastrointestinal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002239
12 extrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012334
13 parathyroid adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002897
14 hypercalcemia 59 32 very rare (1%) Very rare (<4-1%) HP:0003072
15 growth hormone excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000845
16 subcutaneous lipoma 59 32 very rare (1%) Very rare (<4-1%) HP:0001031
17 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
18 episodic abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002574
19 pituitary adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002893
20 adrenocortical adenoma 59 32 very rare (1%) Very rare (<4-1%) HP:0008256
21 neoplasm of the pancreas 59 32 frequent (33%) Frequent (79-30%) HP:0002894
22 neoplasm of the small intestine 59 32 frequent (33%) Frequent (79-30%) HP:0100833
23 intrahepatic cholestasis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001406
24 prolactin excess 59 32 very rare (1%) Very rare (<4-1%) HP:0000870
25 steatorrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002570
26 medullary thyroid carcinoma 59 32 very rare (1%) Very rare (<4-1%) HP:0002865
27 poor appetite 59 32 frequent (33%) Frequent (79-30%) HP:0004396
28 hypochromic microcytic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0004840
29 primary hyperparathyroidism 59 32 very rare (1%) Very rare (<4-1%) HP:0008200
30 intermittent jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0001046
31 lack of bowel sounds 59 32 occasional (7.5%) Occasional (29-5%) HP:0030145
32 gallbladder dysfunction 59 32 frequent (33%) Frequent (79-30%) HP:0005609
33 hypercortisolism 59 Very rare (<4-1%)
34 abnormality of the thyroid gland 59 Very rare (<4-1%)
35 increased circulating cortisol level 32 very rare (1%) HP:0003118
36 abnormality of the abdomen 59 Occasional (29-5%)

UMLS symptoms related to Somatostatinoma:


diarrhea

Drugs & Therapeutics for Somatostatinoma

Drugs for Somatostatinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
2
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
leucovorin Approved Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 6006 143
5
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 43805 6857599 5310940 9887054
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
8 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 59763-91-6
9 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
10 Vitamin B9 Phase 2, Phase 3
11 Immunologic Factors Phase 2, Phase 3,Phase 1
12 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
13 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
14 Folate Phase 2, Phase 3
15 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
16 Antimetabolites Phase 2, Phase 3,Phase 1
17 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
18 Cola Phase 3,Phase 2,Phase 1
19 Central Nervous System Depressants Phase 3
20 Adjuvants, Anesthesia Phase 3
21 Anesthetics, Intravenous Phase 3
22 Analgesics, Opioid Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Anesthetics, General Phase 3
25 Analgesics Phase 3
26 Narcotics Phase 3
27 Anesthetics Phase 3
28
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
29
Somatostatin Approved, Investigational Phase 2,Phase 1 51110-01-1, 38916-34-6 53481605
30
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
31
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
32
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
33
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
34
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
35
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
36
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
37
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
38
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
39
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
40
Streptozocin Approved, Investigational Phase 2 18883-66-4 29327
41
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
42
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
43
Pancrelipase Approved, Investigational Phase 2 53608-75-6
44
Melphalan Approved Phase 2 148-82-3 4053 460612
45
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
46
Gemcitabine Approved Phase 2 95058-81-4 60750
47
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
48
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
49
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
50
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Ga-DOTATOC Versus Octreoscan + CT Completed NCT01869725 Phase 2
4 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
5 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
6 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
7 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
8 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
9 Capecitabine and Temozolomide for Neuroendocrine Cancers Completed NCT00869050 Phase 2 Capecitabine;Temozolomide
10 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
11 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
12 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
13 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
14 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
15 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Active, not recruiting NCT02259725 Phase 2 regorafenib
16 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
17 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
18 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
19 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
20 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
21 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
22 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
23 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
24 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
25 Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Withdrawn NCT00003514 Phase 2 antineoplaston A10;antineoplaston AS2-1
26 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
27 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
28 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
29 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
30 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
31 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
32 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
33 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
34 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
35 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Terminated NCT00730483 Not Applicable PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Somatostatinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: somatostatinoma

Genetic Tests for Somatostatinoma

Anatomical Context for Somatostatinoma

MalaCards organs/tissues related to Somatostatinoma:

41
Pancreas, Liver, Thyroid, Bone, Pituitary, Kidney, Small Intestine
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Somatostatinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Head of Pancreas Affected by disease

Publications for Somatostatinoma

Articles related to Somatostatinoma:

(show top 50) (show all 185)
# Title Authors Year
1
Somatostatinoma Masquerading as Chronic Pancreatitis. ( 29521948 )
2018
2
Mixed mucinous adenocarcinoma and somatostatinoma of the ampulla of Vater associated with neurofibromatosis type 1. ( 28693748 )
2017
3
The Coexistence of Somatostatinoma and Gastrointestinal Stromal Tumor in the Duodenum of a Patient with Von Recklinghausen's Disease. ( 26984078 )
2016
4
Granulomatous Insulitis as a Cause of Acute-Onset Insulin-Dependent Diabetes Mellitus in a Patient With a Pancreatic Endocrine Carcinoma. ( 27160433 )
2016
5
Combined presence of multiple gastrointestinal stromal tumors along with duodenal submucosal somatostatinoma in a patient with neurofibromatosis type 1. ( 27510677 )
2016
6
Somatostatinoma of the minor duodenal papilla associated with pancreas divisum treated by endoscopic papillectomy. ( 27078626 )
2016
7
Novel insights into the polycythemia-paraganglioma-somatostatinoma syndrome. ( 27679736 )
2016
8
Somatostatinoma of the Ampulla: An Incidental Postoperative Finding Following Colorectal Cancer Resection. ( 26958562 )
2016
9
Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia. ( 27081557 )
2015
10
Somatostatinoma of the minor papilla treated by local excision in a patient with neurofibromatosis type 1. ( 25640791 )
2015
11
Pancreatic somatostatinoma diagnosed preoperatively: report of a case. ( 24413789 )
2014
12
Mixed periampullary adenocarcinoma and somatostatinoma with small bowel gastrointestinal stromal tumour in neurofibromatosis type 1. ( 25435578 )
2014
13
Education and imaging. Gastrointestinal: neurofibromatosis type 1, duodenal somatostatinoma and gastrointestinal stromal tumors; a triad worth remembering. ( 24646427 )
2014
14
Ocular Manifestations of Hypoxia-Inducible Factor-2I+ Paraganglioma-Somatostatinoma-Polycythemia Syndrome. ( 25109928 )
2014
15
Endoscopic ultrasound-guided fine-needle aspiration diagnosis of mixed endocrine somatostatinoma of the minor papilla in von Recklinghausen disease. ( 25526415 )
2014
16
Gastric somatostatinoma: an extremely rare cause of upper gastrointestinal bleeding. ( 24143326 )
2013
17
Patient with adult-onset type II citrullinemia beginning 2 years after operation for duodenal malignant somatostatinoma: Indication for liver transplantation. ( 23617280 )
2013
18
Duodenal somatostatinoma: a case report and review of the literature. ( 23618063 )
2013
19
New syndrome of paraganglioma and somatostatinoma associated with polycythemia. ( 23509317 )
2013
20
Case report: recurrent acute pancreatitis secondary to papillary somatostatinoma--a new association. ( 23561978 )
2013
21
Quantum dot immunocytochemical localization of somatostatin in somatostatinoma by Widefield Epifluorescence, super-resolution light, and immunoelectron microscopy. ( 22899862 )
2012
22
Persistent severe gastrointestinal bleeding in a man with metastatic somatostatinoma. ( 21940726 )
2012
23
Endoscopic submucosal dissection of solitary duodenal somatostatinoma (with video). ( 22018555 )
2012
24
Double somatostatinoma and double papillectomy in a patient with type 1 neurofibromatosis (von Recklinghausen's disease). ( 23012013 )
2012
25
Somatostatinoma of the first jejunal loop in a patient with neurofibromatosis von Recklinghausen and bilateral pheochromocytoma. ( 22819908 )
2012
26
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. ( 21831734 )
2011
27
Duodenal somatostatinoma: a case report and review. ( 21437171 )
2011
28
Pancreatic somatostatinoma with obscure inhibitory syndrome and mixed pathological pattern. ( 20043348 )
2010
29
Cardiac metastasis from malignant pancreatic somatostatinoma. ( 19733881 )
2010
30
Pancreatic endocrine carcinoma protruding from the major papilla. ( 20144741 )
2010
31
Hypercalcitonemia revealing a somatostatinoma. ( 20817146 )
2010
32
Asymptomatic somatostatinoma of the pancreatic head: Report of a case. ( 20496141 )
2010
33
Malignant somatostatinoma presenting with diabetic ketoacidosis and inhibitory syndrome: pathophysiologic considerations. ( 20497932 )
2010
34
Mixed endocrine somatostatinoma of the ampulla of vater associated with a neurofibromatosis type 1: a case report and review of the literature. ( 20065557 )
2010
35
Pancreatic somatostatinoma with von Recklinghausen's disease. ( 18926936 )
2009
36
Association of GIST and somatostatinoma in a patient with type-1 neurofibromatosis: is there a common pathway? ( 19223891 )
2009
37
Pancreatic somatostatinoma characterized by extreme hypoglycemia. ( 19719976 )
2009
38
Pancreatic somatostatinoma manifested as severe hypoglycemia. ( 19565056 )
2009
39
A large functional somatostatinoma in the pancreatic tail: atypical CT appearances. ( 20084576 )
2009
40
Pancreatic somatostatinoma and tuberous sclerosis: case report of an exceedingly rare association. ( 18672238 )
2009
41
Clinical challenges and images in GI. Ampullary somatostatinoma associated with neurofibromatosis type 1, presenting with iron-deficiency anemia. ( 19063889 )
2009
42
FNAC diagnosis of pancreatic somatostatinoma. ( 21938182 )
2009
43
Diagnostic usefulness of FDG-PET for malignant somatostatinoma of the pancreas. ( 18795665 )
2008
44
A case of multiple hepatic metastases from pancreatic endocrine carcinoma. ( 18573853 )
2008
45
Diagnosis and treatment of pancreatic somatostatinoma: a case report. ( 19080351 )
2008
46
Somatostatinoma: clinico-pathological features of three cases and literature reviewed. ( 17645474 )
2008
47
Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. ( 18362846 )
2008
48
[Somatostatinoma of the Vater's papilla in a patient with von Recklinghausen's disease]. ( 17438969 )
2007
49
Successful pancreatectomy with en-bloc resection of the celiac artery and portal vein for pancreatic endocrine carcinoma. ( 17629086 )
2007
50
Characterization of the functional and growth properties of long-term cell cultures established from a human somatostatinoma. ( 16601281 )
2006

Variations for Somatostatinoma

Expression for Somatostatinoma

Search GEO for disease gene expression data for Somatostatinoma.

Pathways for Somatostatinoma

Pathways related to Somatostatinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.33 CALCA ENO2 VIP

GO Terms for Somatostatinoma

Cellular components related to Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 CALCA CHGA INS SST VIP
2 neuronal cell body GO:0043025 9.33 CALCA ENO2 SST
3 extracellular space GO:0005615 9.02 CALCA CHGA ENO2 INS SST

Biological processes related to Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.73 CALCA INS SST VIP
2 regulation of signaling receptor activity GO:0010469 9.46 CALCA INS SST VIP
3 cell-cell signaling GO:0007267 9.43 CALCA INS SST
4 regulation of blood pressure GO:0008217 9.4 CALCA CHGA
5 regulation of protein localization GO:0032880 9.37 INS VIP
6 response to heat GO:0009408 9.32 CALCA SST
7 negative regulation of blood vessel diameter GO:0097756 8.96 CHGA INS
8 positive regulation of blood vessel diameter GO:0097755 8.8 CALCA INS VIP

Molecular functions related to Somatostatinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 CALCA INS SST VIP

Sources for Somatostatinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....